on AMOEBA (EPA:ALMIB)
Koppert and Amoéba Collaborate to Launch Biofungicide Solution
Koppert, a leader in biological crop protection, and Amoéba, a Greentech firm, have partnered to launch a biofungicide. The collaboration, formalized by a Memorandum of Understanding, aims to introduce an innovative biofungicide to the market.
Amoéba's product, AXPERA, is an amoeba lysate-based biofungicide targeting fungal diseases. Expected European approval by 2025 and U.S. approval by mid-2025 will soon pave the way for its usage. This partnership seeks to leverage the operational expertise of Koppert to bring AXPERA to market efficiently.
The two companies plan to explore cooperation in distribution, production, registration, and development over the next five months. Koppert and Amoéba aim to strengthen plant health and promote sustainable agriculture through this partnership.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all AMOEBA news